logo
Mirum Pharmaceuticals Appoints Doug Sheehy, JD, as Chief Legal Officer

Mirum Pharmaceuticals Appoints Doug Sheehy, JD, as Chief Legal Officer

Business Wire19-05-2025
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced the appointment of Doug Sheehy, JD, as chief legal officer. Mr. Sheehy brings nearly two decades of experience leading global legal and compliance operations for biopharmaceutical companies.
Mr. Sheehy was most recently chief legal officer and secretary at Sonoma Biotherapeutics, Inc., which is developing regulatory T cell therapies for autoimmune and inflammatory diseases. Prior to Sonoma, from 2016 to 2020, he served as general counsel and secretary for Aimmune Therapeutics, Inc., a biopharmaceutical company that specialized in the development and commercialization of treatments for life-threatening food allergies. Mr. Sheehy served at Aimmune until its acquisition by Nestle Health Science in 2020. Before Aimmune, from 2007-2016, he was executive vice president, chief administrative officer, general counsel, and secretary of Codexis, Inc., a company focused on the development of synthetic enzymes for the pharmaceutical and food industries. Earlier in his career, he served in several roles within the legal department at CV Therapeutics. Mr. Sheehy began his career as a corporate and securities lawyer in Silicon Valley representing emerging growth companies and venture funds. Mr. Sheehy received an A.B. in History from Dartmouth College and a J.D. from American University's Washington College of Law.
'Doug brings extensive global legal experience that will strengthen Mirum's capabilities as we continue to grow our commercial business and advance our rare disease pipeline,' said Chris Peetz, chief executive officer at Mirum. 'Doug will be a great addition to Mirum's leadership team, and I look forward to leveraging his experience in guiding transformative growth for the company.'
'Mirum is an impressive company that has established its place as a leader in rare disease, and I am excited to have the opportunity to join the leadership team and contribute to the exciting work underway,' said Doug Sheehy. 'The company has a focused growth strategy and is poised for continued success as it works to make a meaningful difference in the lives of people impacted by rare disease.'
About Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare diseases affecting children and adults. Mirum has three approved medications: LIVMARLI® (maralixibat) oral solution/LIVMARLI® (maralixibat) tablets, CHOLBAM® (cholic acid) capsules, and CTEXLI™ (chenodiol) tablets.
LIVMARLI, an IBAT inhibitor, is approved for the treatment of two rare liver diseases affecting children and adults. It is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the U.S. (three months and older), in Europe (two months and older), and in other regions globally. It is also approved in the U.S. in cholestatic pruritus in PFIC patients 12 months of age and older; in Europe, it is approved for patients with PFIC three months of age and older. Mirum has initiated the Phase 3 EXPAND study, a label expansion opportunity for LIVMARLI in additional settings of cholestatic pruritus. CHOLBAM is FDA-approved for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders in patients who show signs or symptoms of liver disease.
CTEXLI is FDA-approved for the treatment of cerebrotendinous xanthomatosis (CTX) in adults.
Mirum's late-stage pipeline includes two investigational treatments for several rare diseases.
Volixibat, an IBAT inhibitor, is being evaluated in two potentially registrational studies including the Phase 2 VISTAS study for primary sclerosing cholangitis (PSC) and Phase 2b VANTAGE study for primary biliary cholangitis. Volixibat has been granted Breakthrough Therapy Designation for the treatment of cholestatic pruritus in patients with PBC. Mirum is also planning for a Phase 2 study evaluating MRM-3379, a PDE4D inhibitor for the treatment of Fragile X syndrome, a rare genetic neurocognitive disorder.
To learn more about Mirum, visit mirumpharma.com and follow Mirum on Facebook, LinkedIn, Instagram and Twitter (X).
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Oversold Honeywell (HON) Could Offer Industrial Strength with Dividend Reliability
Oversold Honeywell (HON) Could Offer Industrial Strength with Dividend Reliability

Yahoo

time28 minutes ago

  • Yahoo

Oversold Honeywell (HON) Could Offer Industrial Strength with Dividend Reliability

Honeywell International Inc. (NASDAQ:HON) is included among the 10 Oversold Dividend Stocks to Buy According to Hedge Funds. A shot of a commercial plane with a blur of color in the background, representing the production of auxiliary power units in the Safety and Productivity Solutions segment. The company has been grabbing investors' attention due to its strong dividend policy and robust balance sheet. In its recently announced earnings for the second quarter of 2025, the company reported revenue of $10.35 billion, which showed an 8.09% growth from the same period last year. The revenue surpassed analysts' estimates by $289.2 million. Honeywell International Inc. (NASDAQ:HON) finalized the $2.2 billion acquisition of Sundyne, announced the £1.8 billion purchase of Johnson Matthey's Catalyst Technologies division, and completed the $1.3 billion sale of its PPE business. Operating income rose by 7%, while segment profit increased by 8% to reach $2.4 billion, driven primarily by growth in the Building Automation segment. Honeywell International Inc. (NASDAQ:HON) reported an operating cash flow of $1.3 billion, and its free cash flow was $1 billion, which showed the company's solid cash position. The company ended the quarter with $10.4 billion available in cash and cash equivalents. HON has raised its payouts for 14 consecutive years and offers a quarterly dividend of $1.13 per share. As of July 25, the stock has a dividend yield of 2.02%. While we acknowledge the potential of HON as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure: None.

Jim Cramer Say's Notes That Campbell's Not PepsiCo, But Still in the Same League
Jim Cramer Say's Notes That Campbell's Not PepsiCo, But Still in the Same League

Yahoo

timean hour ago

  • Yahoo

Jim Cramer Say's Notes That Campbell's Not PepsiCo, But Still in the Same League

The Campbell's Company (NASDAQ:CPB) is one of the stocks that Jim Cramer recently commented on. During the episode, Cramer called it a good company as he commented: 'I'm not going to go against a market that's signaling that interest rates are coming down. That's what today did. And the high fliers have flown too high, while the companies with good dividends have gotten too low. This is just temporary. So what are you supposed to do then? First, know that the rotations are not investible, but at best, they're tradable. Take Campbell's or General Mills, both yield almost 5%. Both are good companies, just not as good, maybe not as good as PepsiCo, but they're in the same league… So if people are craving chips and soda again, maybe they'll also crave food from General Mills and Campbell's, neither of which has the calories of Doritos or the chemicals of soda.' Jasni/ Campbell's (NASDAQ:CPB) produces food and beverage products, including soups, sauces, juices, frozen meals, snacks, and bakery items. The company distributes them through retail, foodservice, and e-commerce channels. While we acknowledge the potential of CPB as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio

Jim Cramer Notes 'PepsiCo Sold a Ton of Junk Food.'
Jim Cramer Notes 'PepsiCo Sold a Ton of Junk Food.'

Yahoo

timean hour ago

  • Yahoo

Jim Cramer Notes 'PepsiCo Sold a Ton of Junk Food.'

PepsiCo, Inc. (NASDAQ:PEP) is one of the stocks that Jim Cramer recently commented on. During the episode, Cramer noted that the company 'sold a ton of junk food' despite the rise of GLP-1 weight loss drugs. He remarked: 'PepsiCo's now up almost 20 points from its low. Why? It's important to remember that PepsiCo reported a terrific quarter with sugar water, and Frito-Lay, two categories that were supposed to be on life support thanks to the rise of the GLP-1 weight loss drugs; those injections reduce your craving for junk food. PepsiCo sold a ton of junk food.' ja-san-miguel-xYSp0kkIUio-unsplash PepsiCo (NASDAQ:PEP) produces a wide range of beverages and packaged foods, including snacks, cereals, dairy products, and ready-to-drink offerings, and sparkling water systems. On July 11, Cramer called it a stock 'too cheap relative to its growth rate.' He said: 'If you want to know a stock that's too cheap relative to its growth rate, but nobody talks about it anymore, why don't you check out the stock of PepsiCo? It trades at a stunningly low 17 times earnings. I mean, what gives? Well, how about GLP-1 drugs? How about RFK Junior at Health and Human Services, who despises junk food even as he seems to embrace junk science? How about the desire to stay healthy? All these have weighed on PepsiCo stock. Of course, don't forget they own Frito-Lay. Maybe it's finally overdone. I don't know it. It's a tough industry all of a sudden.' While we acknowledge the potential of PEP as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store